Cabaletta Bio Inc. has announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain.
Innovotex Inc. has acquired an exclusive and perpetual license, facilitated by the Discovery to Impact group at the University of Texas at Austin, to an innovative discovery platform and corresponding patent portfolio to identify and design therapeutic candidates for a range of solid tumor indications.
Revelation Biosciences Inc. has entered into an exclusive worldwide license agreement with Vanderbilt University to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD) for treating or preventing infections.
Mirecule Inc. has entered into a strategic collaboration and exclusive license agreement with Sanofi SA to develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Almirall SA and Simcere Pharmaceutical Group Ltd. have entered into an exclusive licensing agreement for Simcere's IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM-0278.
Seagen Inc. and Lava Therapeutics NV have entered into an exclusive license agreement under which Seagen will work to develop, manufacture and commercialize LAVA-1223, a bispecific T-cell engager designed to target and activate Vγ9Vδ2 T cells in the presence of epidermal growth factor receptor (EGFR)-expressing solid tumors.
Nacuity Pharmaceuticals Inc. and Arctic Therapeutics LLC have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 (N-acetylcysteine amide, NACA) in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA).
Limacorporate S.p.A has outlicensed to Orthofix Medical Inc. new medical technology for patients suffering from chronic high dislocation of the hip. The deal, for U.S. market rights, will see the companies combine the limb-lengthening technology of Orthofix’s Fitbone intramedullary nail system with Limacorporate’s 3D-printed pelvic fixation device to form what Emmanuel Bonhomme, CEO of Limacorporate, told BioWorld is “a personalized and unique complex hip replacement solution.”
Orthocell Ltd. landed its first global licensing deal for its regenerative collagen medical device with Biohorizons Inc., one of the largest dental implant companies in the world. The licensing deal comes on the heels of the Perth, Australia-based company reporting final data from its nerve reconstruction study that showed patients continued to improve between 12- and 24-months post-treatment with its regenerative nerve repair device Remplir.
Shanghai Henlius Biotech Inc. signed an exclusive licensing deal with Organon LLC under which Organon will in-license rights for two of Henlius’ internally developed biosimilar candidates for global commercialization, excluding China, Hong Kong, Macau and Taiwan.
RSS
